Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Honest Company Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Honest Company Inc trades at $5.05 (market cap $543.40M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 5.2× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Honest Company Inc for 39 Days on average.
| DYN | HNST | |
|---|---|---|
Market Cap | $2.81B | $543.40M |
Volume | 2,195,902 | 1,509,522 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $5.95 |
52-Week Low | $14.60 | $2.10 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $2.13B | $447.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
HNST trades at $5.19, up 0.58% today, with a neutral technical signal and mixed earnings performance. The company shows improving cash flow trends with $14.15M net cash flow in 2025, though revenue declined to $371.32M with a net loss of $15.69M. Recent Q2 2026 earnings beat expectations with $0.04 EPS, while strategic exits continue to reshape the business.
The stock presents a turnaround story with improving profitability metrics but faces execution risks amid revenue pressure. Analyst consensus is mixed with a $5.30 price target, representing modest upside potential. Key risks include sustained profitability challenges and competitive pressures in the personal care sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
